New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
06:11 EDTBMRNBioMarin says BMN 165-302 study to be available in Q4 of 2015
BioMarin announced last night that it intends to modify the entry criteria for the BMN 165-302 randomized discontinuation study. "The purpose of the eligibility modification is to leverage those patients who have relatively weaker immune reactions to PEG PAL, who therefore achieve Phe reductions faster, at relatively lower doses and with relatively fewer side effects. Under the revised entry criteria, patients will need to demonstrate a pre-specified reduction in blood Phe from PEG PAL during the BMN 165-301 feeder study prior to entering the BMN 165-302 RDT study," it stated. Based on the changed BMN 165-302 protocol, associated review of the proposed protocol and preliminary BMN 165-301 data with the FDA, and requirement for additional patients, the company now expects data from the enriched BMN 165-302 study to be available in Q4 of 2015.
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
07:55 EDTBMRNBioMarin shares poised to rally, says RBC Capital
RBC Capital expects BioMarin's shares to rally into and through 2015, driven by 4-5 key pipeline events. The firm is especially upbeat on the outlook for Phase II achondroplasia data in 2Q15, as it thinks the product could show promising efficacy in dwarfism. The firm raised its price target on the name to $87 from $77 and keeps an Outperform rating on the shares.
07:44 EDTBMRNBioMarin price target raised to $87 from $74 at UBS
UBS raised its price target on BioMarin to $87 from $74 following its Q3 report and the firm believes the price target could be conservative based on the company's pipeline and its lower risk businesses. UBS reiterates its Buy rating on BioMarin shares.
05:50 EDTBMRNBioMarin remains a top mid cap pick at Piper Jaffray
Subscribe for More Information
October 23, 2014
16:17 EDTBMRNBioMarin lowers FY14 adjusted net loss to ($65M)-($50M) from ($80M)-($60M)
Subscribe for More Information
16:15 EDTBMRNBioMarin raises FY14 revenue view to $700M-$710M from $680M-$700M
Subscribe for More Information
16:13 EDTBMRNBioMarin reports Q3 adjusted EPS (16c), consensus (23c)
Subscribe for More Information
15:30 EDTBMRNNotable companies reporting after market close
Subscribe for More Information
October 21, 2014
09:48 EDTBMRNShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
October 20, 2014
07:10 EDTBMRNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use